IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY
Publication
, Conference
Carella, A-M; Ravandi, F; Ritchie, EK; Sayar, H; Lancet, JE; Craig, MD; Vey, N; Strickland, SA; Schiller, GJ; Jabbour, E; Erba, HP; Pigneux, A ...
Published in: HAEMATOLOGICA
October 1, 2015
Duke Scholars
Published In
HAEMATOLOGICA
ISSN
0390-6078
Publication Date
October 1, 2015
Volume
100
Start / End Page
1 / 1
Location
Florence, ITALY
Publisher
FERRATA STORTI FOUNDATION
Conference Name
45th Congress of the Italian-Society-of-Hematology
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Carella, A.-M., Ravandi, F., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M. D., … Stuart, R. K. (2015). IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY. In HAEMATOLOGICA (Vol. 100, pp. 1–1). Florence, ITALY: FERRATA STORTI FOUNDATION.
Carella, A. -. M., F. Ravandi, E. K. Ritchie, H. Sayar, J. E. Lancet, M. D. Craig, N. Vey, et al. “IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY.” In HAEMATOLOGICA, 100:1–1. FERRATA STORTI FOUNDATION, 2015.
Carella A-M, Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, et al. IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2015. p. 1–1.
Carella, A. .. M., et al. “IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY.” HAEMATOLOGICA, vol. 100, FERRATA STORTI FOUNDATION, 2015, pp. 1–1.
Carella A-M, Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst H-A, Recher C, Klimek VM, Cortes J, Roboz GJ, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Kantarjian HM, Stuart RK. IMPROVED SURVIVAL IN PATIENTS >= 60 WITH FIRST RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA TREATED WITH VOSAROXIN PLUS CYTARABINE VS PLACEBO PLUS CYTARABINE: RESULTS FROM THE PHASE 3 VALOR STUDY. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2015. p. 1–1.
Published In
HAEMATOLOGICA
ISSN
0390-6078
Publication Date
October 1, 2015
Volume
100
Start / End Page
1 / 1
Location
Florence, ITALY
Publisher
FERRATA STORTI FOUNDATION
Conference Name
45th Congress of the Italian-Society-of-Hematology
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology